Topical Tretinoin Therapy and All-Cause Mortality

Weinstock, Martin A.; Bingham, Stephen F.; Lew, Robert A.; Hall, Russell P.; Eilers, David; Kirsner, Robert S.; Naylor, Mark F.; Kalivas, James; Cole, Gary W.; Marcolivio, Kimberly; Collins, Joseph P.; DiGiovanna, John J.; Vertrees, Julia E.

doi:10.1001/archdermatol.2008.542

Cited by 46 publications

(42 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…124 In addition, topical retinoids used for prolonged periods were associated with increased mortality in a single study, although some investigators have discounted this result as spurious. 125 Oral retinoids (acitretin, oral retinol, and isotretinoin) also do not appear to reduce the incidence of BCC in those with a history of a keratinocyte cancer. [126][127][128][129] Limited evidence is available to support the utility of other agents, including oral nicotinamide, a-difluoromethylornithine, and celecoxib, in reducing the risk for keratinocyte cancer in patients with history of BCC.…”

Section: Follow-up and Reducing Risk For Future Skin Cancersmentioning

confidence: 99%

See 1 more Smart Citation

Guidelines of care for the management of basal cell carcinoma

Baum¹,

Bordeaux²,

Brown³

et al. 2018

Journal of the American Academy of Dermatology

315

219

View full text Add to dashboard Cite

Basal cell carcinoma (BCC) is the most common form of human cancer, with a continually increasing annual incidence in the United States. When diagnosed early, the majority of BCCs are readily treated with office-based therapy, which is highly curative. In these evidence-based guidelines of care, we provide recommendations for the management of patients with BCC, as well as an in-depth review of the best available literature in support of these recommendations. We discuss biopsy techniques for a clinically suspicious lesion and offer recommendations for the histopathologic interpretation of BCC. In the absence of a formal staging system, the best available stratification based on risk for recurrence is reviewed. With regard to treatment, we provide recommendations on treatment modalities along a broad therapeutic spectrum, ranging from topical agents and superficially destructive modalities to surgical techniques and systemic therapy. Finally, we review the available literature and provide recommendations on prevention and the most appropriate follow-up for patients in whom BCC has been diagnosed. ( J Am Acad Dermatol

show abstract

Section: Follow-up and Reducing Risk For Future Skin Cancersmentioning

confidence: 99%

“…[116][117][118][119]123,[125][126][127][128][129][130][131][132][133][134][135][136][137][138][139][140][141] …”

Section: Follow-up and Reducing Risk For Future Skin Cancersunclassified

Guidelines of care for the management of basal cell carcinoma

Baum¹,

Bordeaux²,

Brown³

et al. 2018

Journal of the American Academy of Dermatology

315

219

View full text Add to dashboard Cite

show abstract

“…However, they should be used regularly on lesion-prone skin to produce improvement [44]. Also, absorption rates of topical application are different from formations and certain circumstances [40]. Generally, systemic supplementation is recommended for chemoprevention for skin cancer [44], and most RCTs were conducted by using oral supplementation.…”

Section: Discussionmentioning

confidence: 99%

“…We excluded 18 articles [25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42] for the following reasons: description of only study protocol or rationale (n = 4) [25,26,27,28], precancerous lesions or nonskin cancer as outcome measures (n = 12) [29,30,31,32,33,34,35,36,37,38,39,40], and use of supplements not relevant to the current study subject (n = 2) [41,42]. …”

Section: Methodsmentioning

confidence: 99%

Effects of Vitamin Treatment or Supplements with Purported Antioxidant Properties on Skin Cancer Prevention: A Meta-Analysis of Randomized Controlled Trials

Chang

Myung

Chung³

et al. 2011

Dermatology

View full text Add to dashboard Cite

Aims: To investigate the effect of vitamin treatment or supplements with purported antioxidant properties on the primary and secondary prevention of skin cancer using a meta-analysis of randomized controlled trials (RCTs). Methods: We searched PubMed, Embase and the Cochrane Library in June 2009. Among 398 articles searched, 11 articles on 10 RCTs were included in the final analysis. Results: In a fixed-effects meta-analysis of all 10 trials, vitamin treatment or supplements with purported antioxidant properties were found to have no preventive effect on skin cancer [relative risk (RR) = 0.98; 95% confidence interval (CI) = 0.94–1.03]. Similar findings were observed in a subgroup meta-analysis of 10 studies on both primary prevention trials (RR = 0.98; 95% CI = 0.93–1.03) and secondary prevention trials (RR = 0.97; 95% CI = 0.83–1.13). Further, subgroup meta-analyses revealed no preventive effect on cancer by type of antioxidant, type of cancer and the methodological quality of the studies. Conclusion: The current meta-analysis of RCTs indicated that there is no clinical evidence to support an overall primary and secondary preventive effect of vitamin treatment or supplements with purported antioxidant properties on skin cancer. The effect of vitamin supplements on skin cancer should not be overemphasized.

show abstract

“…2 Although serious events have rarely been reported, the safety profile came into question after results of increased mortality among participants receiving treatment with topical tretinoin in one trial. 3 In 2005, Weinstock et al 3 presented an abstract reporting the early termination of the Veterans Affairs Topical Tretinoin Chemoprevention (VATTC) trial. The VATTC trial was a randomized, placebocontrolled study investigating whether topical tretinoin 0.1% cream could prevent the development of nonmelanoma skin cancer in elderly patients during a 2-to 6-year follow-up period.…”

mentioning

confidence: 99%